Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017067530) COMBINATION TREATING PROSTATE CANCER, PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/067530 International Application No.: PCT/CN2017/073380
Publication Date: 27.04.2017 International Filing Date: 13.02.2017
IPC:
A61K 31/517 (2006.01) ,A61K 31/4166 (2006.01) ,A61P 35/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
517
ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
4164
1,3-Diazoles
4166
having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
康朴生物医药技术(上海)有限公司 KANGPU BIOPHARMACEUTICALS, LTD. [CN/CN]; 中国上海市 浦东新区张江高科技园区蔡伦路780号818室 Suite 818, 780 Cailun Road, Zhangjiang Hi-Tech Park, Pudong New Area Shanghai 201203, CN
Inventors:
戈传生 GE, Chuansheng; CN
廖柏松 LIAO, Baisong; CN
李文成 LEE, Wen-Cherng; CN
Agent:
上海弼兴律师事务所 SHANGHAI BESHINING LAW OFFICE; 中国上海市 小木桥路681号外经大厦21楼 21st Floor, SFECO Mansion, No.681 Xiaomuqiao Road Shanghai 200032, CN
Priority Data:
Title (EN) COMBINATION TREATING PROSTATE CANCER, PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD
(FR) ASSOCIATION MÉDICAMENTEUSE POUR LE TRAITEMENT DU CANCER DE LA PROSTATE, COMPOSITION PHARMACEUTIQUE ET MÉTHODE DE TRAITEMENT
(ZH) 一种治疗前列腺癌的组合、药物组合物及治疗方法
Abstract:
(EN) Disclosed are a combination treating prostate cancer, a pharmaceutical composition and a treatment method. The combination includes one of a benzoheterocyclic compound as shown in formula (I), a pharmaceutically acceptable salt thereof, a solvate thereof, a crystalline form thereof, a co-crystal thereof, a stereoisomer thereof, an isotope compound thereof, a metabolite thereof and a prodrug thereof, and an androgen receptor pathway modulator. The combination, the pharmaceutical composition thereof and the treatment method inhibit prostate cancer in a more effective manner.
(FR) L'invention concerne une association médicamenteuse pour le traitement du cancer de la prostate, une composition pharmaceutique et une méthode de traitement. L'association médicamenteuse comprend un composé benzohétérocyclique tel que représenté par la formule (I), un sel pharmaceutiquement acceptable de celui-ci, un solvate de celui-ci, une forme cristalline de celui-ci, un co-cristal de celui-ci, un stéréoisomère de celui-ci, un composé isotope de celui-ci, un métabolite de celui-ci et un promédicament de celui-ci, et un modulateur de la voie du récepteur androgène. L'association médicamenteuse, la composition pharmaceutique associée et la méthode de traitement inhibent le cancer de la prostate de manière plus efficace.
(ZH) 本发明公开了一种治疗前列腺癌的组合、药物组合物及治疗方法。本发明公开的组合包含通式(I)所示的苯并杂环化合物、其药学上可接受的盐、溶剂化物、晶型、共晶、立体异构体、同位素化合物、代谢物和前药中的一种,以及雄激素受体通路调节剂。本发明的组合、其药物组合物及治疗方法能够更有效地抑制前列腺癌。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)